EGCG: Clinical Trials

11 trials of EGCG, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 4 unknown, 1 suspended, 1 terminated. 11 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 211Completed 4, Unknown 4, Suspended 1, Terminated 1, Withdrawn 1
Phase 12Unknown 2
Phase 31Completed 1

Follow EGCG: new trials by email Literature Review of EGCG trials Research Report on EGCG

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Reducing Frailty for Older Cancer Survivors Using Supplements II
Epigallocatechin-3-Gallate (EGCG), Microcrystalline cellulose (MCC), Ascorbic Acid (Vitamin C) - Frailty, Inflammation
Phase 2SuspendedUniversity of Rochester1182024-10-252026-06-26
Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia
EGCG - Pneumonia, Interstitial, Cancer Patients
Phase 2CompletedShandong Cancer Hospital and Institute1112023-06-052025-11-28
Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients
EGCG - Interstitial Pneumonia, Neoplasms Malignant
Phase 1 / Phase 2UnknownShandong Cancer Hospital and Institute782023-01-052023-05-30
Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy
EGCG, mLDG - Lung Neoplasms, Esophagitis
Phase 2UnknownShandong Cancer Hospital and Institute832015-04-012020-04-28
Effect of Epigallocatechin -3-gallate Supplementation in Traumatic Brain Injury Patients
EGCG, Placebo (deionized water) - Traumatic Brain Injury
Phase 2 / Phase 3CompletedNational Nutrition and Food Technology Institute302015-03-012016-06-07
Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy
EGCG, placebo - Breast Neoplasms, Dermatitis
Phase 2UnknownShandong Cancer Hospital and Institute682014-12-012019-04-05
"Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome" (TESFX)
EGCG, Placebo, Cognitive training - Fragile X Syndrome
Phase 2CompletedParc de Salut Mar442013-06-112019-05-10
A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)
Epigallocatechin-3-gallate (EGCG), Placebo - Light Chain (AL) Amyloidosis, Cardiac Involvement
Phase 2CompletedFlorian Michel382013-04-012017-10-17
Study of Topically Applied Green Tea Extract for Radio Dermatitis and Radiation Mucositis
EGCG - Epigallocatechin Gallate, Radio Dermatitis
Phase 1 / Phase 2UnknownShandong Cancer Hospital and Institute152011-09-012020-04-28
Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II
Polyphenon E, Placebo - Multiple Sclerosis
Phase 2TerminatedLouisiana State University Health Sciences Center in New Orleans112011-07-012014-03-14
Effect of EGCG on the Body's Response to Insulin
EGCG - Hypertension, Obesity
Phase 2WithdrawnUniversity of Maryland, Baltimore2007-02-012022-03-04

Conditions studied

Inflammation (2)  ·  Lung Diseases, Interstitial (2)  ·  Amyloidosis (1)  ·  Brain Injuries, Traumatic (1)  ·  Breast Neoplasms (1)  ·  Dermatitis (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Esophagitis (1)  ·  Fragile X Syndrome (1)  ·  Frailty (1)  ·  Hypertension (1)  ·  Insulin Resistance (1)  ·  Lung Neoplasms (1)  ·  Multiple Sclerosis (1)  ·  Neoplasms (1)

Sponsors

Shandong Cancer Hospital and Institute (5)  ·  Florian Michel (1)  ·  Louisiana State University Health Sciences Center in New Orleans (1)  ·  National Nutrition and Food Technology Institute (1)  ·  Parc de Salut Mar (1)  ·  University of Maryland, Baltimore (1)  ·  University of Rochester (1)

Countries

United States (3)  ·  China (2)  ·  Germany (1)  ·  Iran (1)  ·  Spain (1)

Top investigators

Ligang Xing, MD,PhD (2)  ·  Jesus F Lovera, MD (1)  ·  Jinming Yu, M.D. (1)  ·  Kashif Munir, MD (1)  ·  Ligang Xing, MD, PhD (1)  ·  Rafael de la Torre, PhamD (1)  ·  Xing Ligang, MD,PhD (1)

Results publications

PMID 24444526, PMID 26298797, PMID 35648426, PMID 37620508, PMID 38632501, PMID 41549240

NIH funding

K23AT004433 (1)